Abstract:
:Management of early stages of Hodgkin's disease requires development of treatment programs that are nominally toxic, with a low likelihood of sterility and secondary malignancies, both associated with alkylating agents. Although patients with laparotomy-staged disease without B symptoms or large mediastinal masses have good results when treated with radiotherapy alone, patients with adverse features need chemotherapy for optimal disease-free survival results. MOPP and its variants have been studied extensively for adjuvant therapy of patients with early staged disease but are associated with the development of secondary malignancies, including acute leukemia and solid tumors. ABVD has been compared with MOPP in combination with radiation therapy for patients with stages IIB and IIIB, and ABVD is not associated with a high risk of acute leukemia; however, cardiac and pulmonary toxicities have been reported, and there may be long term complications following ABVD in combined modality programs. In 1988, we developed NOVP [mitoxantrone (Novantrone), vincristine, vinblastine, prednisone], designed as adjuvant chemotherapy to treat patients with clinically staged I-II Hodgkin's disease who had unfavorable features, including B symptoms, large mediastinal masses, and hilar lymph node involvement. We also included patients with peripheral masses > or = 10 cms and those with stage III disease. In the second phase of this study, we treated patients without adverse features, in order to avoid laparotomy. The treatment plan included three cycles of NOVP, followed by radiotherapy to the mantle and the abdomen, with fields depending upon disease presentation. Patients with large mediastinal masses or hilar involvement also received low dose lung radiotherapy.(ABSTRACT TRUNCATED AT 250 WORDS)
journal_name
Leuk Lymphomajournal_title
Leukemia & lymphomaauthors
Hagemeister FBdoi
10.3109/10428199309149119subject
Has Abstractpub_date
1993-01-01 00:00:00pages
91-7eissn
1042-8194issn
1029-2403journal_volume
10 Supplpub_type
杂志文章abstract::Recently, lenalidomide and low dose dexamethasone were found to result in superior overall survival compared to lenalidomide and high dose dexamethasone. The immune suppressive effects of dexamethasone can antagonize lenalidomide immunomodulatory activity and may explain this observation. We conducted a retrospective ...
journal_title:Leukemia & lymphoma
pub_type: 临床试验,杂志文章,多中心研究
doi:10.3109/10428191003721342
更新日期:2010-06-01 00:00:00
abstract::A new Ph1-positive acute lymphoblastic leukemia cell line, designated as ALL/MIK, has been developed from a patient with Ph1-positive acute leukemia. The ALL/MIK cells showed an immunophenotype of common ALL with rearranged JH and Jk genes. The ALL/MIK cells showed no M-bcr rearrangement using Southern blot analysis w...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199409059601
更新日期:1994-01-01 00:00:00
abstract::Adhesion molecules such as CD2 and its ligand CD58 (LFA-3), as well as CD11a/18 (LFA-1) and CD54 (ICAM-1) regulate not only cell to cell attachment but also participate in lymphocyte activation, recirculation, and effector function including cytolytic activity towards tumor cells. We have investigated the role of CD2/...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199309147353
更新日期:1993-05-01 00:00:00
abstract::Apoptosis, the caspase-mediated cell death, plays an important role in the etiology, pathogenesis and therapy of a variety of diseases. Abnormalities of apoptosis regulation, resulting in either its inhibition or enhancement, play a key role in the development of various malignant hematological disorders. Several rout...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.1080/1042819031000077007
更新日期:2003-07-01 00:00:00
abstract::The WT1 gene is essential for kidney development and is mutated in some Wilms tumours. It is also expressed at a high level in many acute leukaemias and in some haematopoietic progenitor cells, and mutations have been found in leukaemias. The function of WT1, which is a zinc finger protein and has domains characterist...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199709059677
更新日期:1997-10-01 00:00:00
abstract::This study was designed to investigate the immunostimulatory effect of low dose Il-2 treatment in B-CLL patients previously treated with 2-chlorodeoxyadenosine (2CdA) in whom severe depletion of T lymphocyte subsets was observed. Four patients enrolled into the study had previously been treated with 3-6 courses of 2Cd...
journal_title:Leukemia & lymphoma
pub_type: 临床试验,杂志文章
doi:10.3109/10428199909050958
更新日期:1999-07-01 00:00:00
abstract::Bullous pyoderma gangrenosum begins as a bulla, nodule or nonulcerated erythematous plaque that blisters or ulcerates to form a superficial ulcer surrounded by a hemorrhagic, bullous border, which is surrounded by a blue-gray halo. Bullous pyoderma gangrenosum is most commonly associated with hematologic malignancies,...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190500254299
更新日期:2006-01-01 00:00:00
abstract::Multiple myeloma (MM) often presents with unspecific symptoms and is challenging to diagnose. We performed this DSMM/EMN-analysis via test-(retro-) and validation (prospective) study to determine the time interval from the onset of first symptoms to the diagnosis of MM. The retrospective and prospective analyses were ...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428194.2019.1695051
更新日期:2020-04-01 00:00:00
abstract::Progress in chronic lymphocytic leukemia (CLL) therapies has extended greatly the length and depth of remission, with the goal of treatment advancing towards a cure for some patients. Accordingly, clinical endpoints must evolve to capture these outcomes, and to provide faster access to novel therapies. Minimal residua...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.1080/10428194.2017.1318439
更新日期:2017-12-01 00:00:00
abstract::Peripheral T-cell lymphomas are characterized by a poor clinical outcome. We retrospectively analyzed 208 adults treated in our institution between 2000 and 2011. Median age at diagnosis was 55 years. Fifty-one percent had B symptoms and 51% serum elevated lactate dehydrogenase (LDH) levels. Eastern Cooperative Oncolo...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2013.776680
更新日期:2013-11-01 00:00:00
abstract::The relationship between histopathologic characteristics and treatment outcomes in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab-based immunochemotherapy needs re-evaluation. Patients with newly diagnosed DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednis...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2011.588761
更新日期:2011-10-01 00:00:00
abstract::Monitoring of t(14;18) in blood or bone marrow in follicular lymphoma (FL) remains controversial. We attempted to monitor t(14;18) in lymph nodes by ultrasound-guided fine needle aspirations (UG-FNA). First, we confirmed t(14;18) in 27/31 UG-FNAs of lymph nodes with fluorescent in situ hybridisation (FISH) and/or poly...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190902927005
更新日期:2009-07-01 00:00:00
abstract::The human analogue of the mouse double minute-2 (MDM-2) protein binds to p53 protein and abrogates its tumor-suppressing activity. MDM-2 overexpression may represent an alternative mechanism to p53 mutation for escaping the p53-mediated growth control. Interestingly, multiple MDM-2 protein isoforms have been described...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199509051698
更新日期:1995-03-01 00:00:00
abstract::The purpose of this study was to better define the clinical features and natural history of peripheral T-cell lymphomas (PTCL) entities included in the Revised European American lymphoma (REAL) classification. Cases of PTCL were retrieved from the records of the Department of Pathology and classified according to the ...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.1080/1042819021000030054
更新日期:2003-02-01 00:00:00
abstract::Pixantrone is a potentially more effective, less cardiotoxic alternative to doxorubicin for patients with aggressive non-Hodgkin lymphoma (aNHL). This phase I/II non-comparative study evaluated pixantrone in place of doxorubicin in the standard CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone),...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2010.546016
更新日期:2011-04-01 00:00:00
abstract::The human germinal center-associated lymphoma (HGAL) gene has prognostic value in diffuse large B-cell lymphoma, and expression of its cognate protein is germinal center-specific. A previous study had suggested that HGAL protein expression might also be related to the outcome in patients with Hodgkin lymphoma (HL). Th...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428190903242628
更新日期:2009-11-01 00:00:00
abstract::Isolated myeloid sarcoma (MS) is a rare extramedullary presentation of acute myeloid leukemia (AML). Little is known about MS outcomes due to its rarity. A population-based analysis of MS using the Survival, Epidemiology, and End Results (SEER) database was performed. We identified 345 patients, aged 15 or older, diag...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2014.963080
更新日期:2015-06-01 00:00:00
abstract::Two cases of polycythemia vera (PV) had transition to a hematological condition compatible with chronic neutrophilic leukemia (CNL) 17 and 8 years after diagnosis, respectively. One patient was treated with carboquone followed by hydroxyurea (HU) and the other with HU during PV phase. On transition, both had neutrophi...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199909093744
更新日期:1999-03-01 00:00:00
abstract::131 patients with Philadelphia (Ph') chromosome positive chronic myelogenous leukemia (CML) were treated with interferon (IFN) alpha or a combination of IFN alpha and IFN gamma. In study, 1, 13 not pretreated and 41 pretreated patients, 48 in chronic phase disease, 6 in accelerated phase, received 4 x 10(6) U/m2 IFN a...
journal_title:Leukemia & lymphoma
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.3109/10428199309148513
更新日期:1993-01-01 00:00:00
abstract::Adult T-cell leukemia/lymphoma (ATL) is frequently a very aggressive malignancy with a poor survival despite aggressive multiagent chemotherapy. The combination of the antiretroviral drug zidovudine (AZT) and interferon alpha (IFNalpha) has been reported to induce remissions in patients with ATL. The purpose of this s...
journal_title:Leukemia & lymphoma
pub_type: 临床试验,杂志文章,多中心研究
doi:10.3109/10428190109057927
更新日期:2001-01-01 00:00:00
abstract::The aim of the present study was to evaluate the efficacy of the combination of fludarabine 30/mg/m2 + cytarabine 2g/m2 followed by the administration of G-CSF to achieve a complete remission (CR) in patients with relapsed acute lymphoblastic leukemia (ALL). We treated twelve patients in first relapse, overall 10 pati...
journal_title:Leukemia & lymphoma
pub_type: 临床试验,杂志文章
doi:10.3109/10428199709039047
更新日期:1997-05-01 00:00:00
abstract::There is little information in the literature on outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. The purpose of this study was to analyze The University of Texas M.D. Anderson Cancer Center results in such patients. From 1985 to 1998, 39 patients ...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/1042819021000006277
更新日期:2002-09-01 00:00:00
abstract::Since unlimited proliferative potential has been identified as a major and, to date, therapeutically unexploited phenotypic hallmark of cancer, telomere maintenance mechanisms have been proposed as potential targets for new anticancer interventions. This study was aimed to investigate the effects of BIBR1532, the lead...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2012.704034
更新日期:2013-03-01 00:00:00
abstract::High-dose melphalan therapy with peripheral blood stem cell (PBSC) transplantation is a standard treatment for younger patients with untreated multiple myeloma that results in high overall and complete response (CR) rates, and improved event-free and overall survival compared with standard chemotherapy alone. Inductio...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.1080/10428190701540991
更新日期:2007-10-01 00:00:00
abstract::B-cell chronic lymphocytic leukemia (CLL) is a clonal B cell malignancy of morphologically mature, functionally immature B cells. B-cell CLL cells are known to be resistant to killing by anticancer and other agents. This resistance is associated with alterations in apoptosis and cell cycle regulated genes. In our earl...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/1042819021000006411
更新日期:2002-09-01 00:00:00
abstract::One of the severe toxicities of pegaspargase (PEG) is the development of allergic reactions. This study retrospectively assessed 311 PEG doses administered to 139 acute lymphoblastic leukemia patients from May 1, 2008 to July 30, 2014 for allergic reactions based on the Common Terminology Criteria for Adverse Events (...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2015.1105369
更新日期:2016-07-01 00:00:00
abstract::An analysis by month of diagnosis was made of 1359 cases of Hodgkins disease (HD) on the Scotland and Newcastle Lymphoma Group (SNLG) registry 1979-1992 to look for evidence of seasonality. A March peak was evident when all cases were analysed (p < 0.01). The histological subtypes nodular sclerosing (NS) and mixed cel...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199509059625
更新日期:1995-07-01 00:00:00
abstract::The patient granulocyte-colony stimulating factor (G-CSF) response is represented by the leukocyte peak in the blood induced by a single dose of G-CSF after chemotherapy, and is correlated with subsequent neutropenic infection risk. General patterns for a meaningful risk group stratification, have not yet been determi...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,多中心研究
doi:10.3109/10428194.2014.919631
更新日期:2015-02-01 00:00:00
abstract::Imatinib, which has revolutionized chronic myeloid leukemia (CML) treatment, was suggested to improve lipid profile. Statins, a dyslipidemia drug, were reported to potentiate imatinib's antileukemic effect. However, analysis of imatinib combined with statins is lacking. We have retrospectively analyzed the normalizati...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428194.2016.1228928
更新日期:2017-05-01 00:00:00
abstract::Conventional G-banding cytogenetics (CC) detects chromosome 17 (chr17) abnormalities in 2% of patients with de novo myelodysplastic syndromes (MDS). We used CC and fluorescence in situ hybridization (FISH) (LSI p53/17p13.1) to assess deletion of 17p in 531 patients with de novo MDS from the Spanish Group of Hematologi...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,多中心研究
doi:10.3109/10428194.2015.1028053
更新日期:2015-01-01 00:00:00